Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PhRMA Amplifies Push For Comprehensive Health Care Reform

Executive Summary

The Pharmaceutical Research and Manufacturers of America is stepping up its campaign to promote passage of a health care reform bill as Congress starts its August recess without having had a vote on the floor of either chamber

You may also be interested in...

House Energy And Commerce Adds Pharma Provisions To Health Reform Bill

The House Energy and Commerce Committee made a number of changes during markup of the America's Affordable Health Choices Act that will affect the pharmaceutical industry

The 77% Solution: Obama Rx Drug Overpayment Claim Culled From McKinsey Report

Former McKinsey executive and Obama health team member Kocher is the source behind Obama claim made during town hall tour to win over support for health reform.

Can Pharma Industry Afford To Give Up More For Health Reform? PhRMA Calls President "Misinformed"

Pharmaceutical Research and Manufacturers trade group responds to President Obama's claim that the pharmaceutical industry can afford to give up more than the $80 billion previously agreed to.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts